Giuseppe Patti1, Ladislav Pecen2,3, Giuseppina Casalnuovo4, Marius Constantin Manu4, Paulus Kirchhof5,6,7, Raffaele De Caterina8. 1. Department of Translational Medicine, Maggiore della Carità Hospital, University of Eastern Piedmont, Via Solaroli 17, 28100, Novara, Italy. giuseppe.patti@uniupo.it. 2. Institute of Computer Science of the Czech Academy of Sciences, Prague, Czech Republic. 3. Medical Faculty, Charles University, Pilsen, Czech Republic. 4. Daiichi Sankyo Europe, Munich, Germany. 5. Department of Cardiology, University Heart and Vascular Centre UKE, Hamburg, Germany. 6. Institute of Cardiovascular Sciences, University of Birmingham, SWBH and UHB NHS Trusts, Birmingham, UK. 7. The Atrial Fibrillation NETwork (AFNET, Münster, Germany. 8. University Cardiology Division, Cardiovascular and Thoracic Department, Pisa University Hospital, University of Pisa, Via Paradisa, 2, 56124, Pisa, Italy. raffaele.decaterina@unipi.it.
Abstract
BACKGROUND: Recent data have suggested that insulin-requiring diabetes mostly contributes to the overall increase of thromboembolic risk in patients with atrial fibrillation (AF) on warfarin. We evaluated the prognostic role of a different diabetes status on clinical outcome in a large cohort of AF patients treated with edoxaban. METHODS: We accessed individual patients' data from the prospective, multicenter, ETNA-AF Europe Registry. We compared the rates of ischemic stroke/transient ischemic attack (TIA)/systemic embolism, myocardial infarction (MI), major bleeding and all-cause death at 2 years according to diabetes status. RESULTS: Out of an overall population of 13,133 patients, 2885 had diabetes (22.0%), 605 of whom (21.0%) were on insulin. The yearly incidence of ischemic stroke/TIA/systemic embolism was 0.86% in patients without diabetes, 0.87% in diabetic patients not receiving insulin (p = 0.92 vs no diabetes) and 1.81% in those on insulin (p = 0.002 vs no diabetes; p = 0.014 vs diabetes not on insulin). The annual rates of MI and major bleeding were 0.40%, 0.43%, 1.04% and 0.90%, 1.10% and 1.71%, respectively. All-cause yearly mortality was 3.36%, 5.02% and 8.91%. At multivariate analysis, diabetes on insulin was associated with a higher rate of ischemic stroke/TIA/systemic embolism [adjusted HR 2.20, 95% CI 1.37-3.54, p = 0.0011 vs no diabetes + diabetes not on insulin] and all-cause death [aHR 2.13 (95% CI 1.68-2.68, p < 0.0001 vs no diabetes]. Diabetic patients not on insulin had a higher mortality [aHR 1.32 (1.11-1.57), p = 0.0015], but similar incidence of stroke/TIA/systemic embolism, MI and major bleeding, vs those without diabetes. CONCLUSIONS: In a real-world cohort of AF patients on edoxaban, diabetes requiring insulin therapy, rather than the presence of diabetes per se, appears to be an independent factor affecting the occurrence of thromboembolic events during follow-up. Regardless of the diabetes type, diabetic patients had a lower survival compared with those without diabetes.
BACKGROUND: Recent data have suggested that insulin-requiring diabetes mostly contributes to the overall increase of thromboembolic risk in patients with atrial fibrillation (AF) on warfarin. We evaluated the prognostic role of a different diabetes status on clinical outcome in a large cohort of AF patients treated with edoxaban. METHODS: We accessed individual patients' data from the prospective, multicenter, ETNA-AF Europe Registry. We compared the rates of ischemic stroke/transient ischemic attack (TIA)/systemic embolism, myocardial infarction (MI), major bleeding and all-cause death at 2 years according to diabetes status. RESULTS: Out of an overall population of 13,133 patients, 2885 had diabetes (22.0%), 605 of whom (21.0%) were on insulin. The yearly incidence of ischemic stroke/TIA/systemic embolism was 0.86% in patients without diabetes, 0.87% in diabetic patients not receiving insulin (p = 0.92 vs no diabetes) and 1.81% in those on insulin (p = 0.002 vs no diabetes; p = 0.014 vs diabetes not on insulin). The annual rates of MI and major bleeding were 0.40%, 0.43%, 1.04% and 0.90%, 1.10% and 1.71%, respectively. All-cause yearly mortality was 3.36%, 5.02% and 8.91%. At multivariate analysis, diabetes on insulin was associated with a higher rate of ischemic stroke/TIA/systemic embolism [adjusted HR 2.20, 95% CI 1.37-3.54, p = 0.0011 vs no diabetes + diabetes not on insulin] and all-cause death [aHR 2.13 (95% CI 1.68-2.68, p < 0.0001 vs no diabetes]. Diabetic patients not on insulin had a higher mortality [aHR 1.32 (1.11-1.57), p = 0.0015], but similar incidence of stroke/TIA/systemic embolism, MI and major bleeding, vs those without diabetes. CONCLUSIONS: In a real-world cohort of AF patients on edoxaban, diabetes requiring insulin therapy, rather than the presence of diabetes per se, appears to be an independent factor affecting the occurrence of thromboembolic events during follow-up. Regardless of the diabetes type, diabetic patients had a lower survival compared with those without diabetes.
Authors: A John Camm; Gregory Y H Lip; Raffaele De Caterina; Irene Savelieva; Dan Atar; Stefan H Hohnloser; Gerhard Hindricks; Paulus Kirchhof Journal: Eur Heart J Date: 2012-08-24 Impact factor: 29.983
Authors: A John Camm; Paulus Kirchhof; Gregory Y H Lip; Ulrich Schotten; Irene Savelieva; Sabine Ernst; Isabelle C Van Gelder; Nawwar Al-Attar; Gerhard Hindricks; Bernard Prendergast; Hein Heidbuchel; Ottavio Alfieri; Annalisa Angelini; Dan Atar; Paolo Colonna; Raffaele De Caterina; Johan De Sutter; Andreas Goette; Bulent Gorenek; Magnus Heldal; Stefan H Hohloser; Philippe Kolh; Jean-Yves Le Heuzey; Piotr Ponikowski; Frans H Rutten Journal: Eur Heart J Date: 2010-08-29 Impact factor: 29.983
Authors: Giuseppe Patti; Elisabetta Cerchiara; Edoardo Bressi; Barbara Giannetti; Alessia Delli Veneri; Germano Di Sciascio; Giuseppe Avvisati; Raffaele De Caterina Journal: Am J Cardiol Date: 2019-12-09 Impact factor: 2.778
Authors: Giuseppe Patti; Markus Lucerna; Ilaria Cavallari; Elisabetta Ricottini; Giulia Renda; Ladislav Pecen; Fabio Romeo; Jean-Yves Le Heuzey; Josè Luis Zamorano; Paulus Kirchhof; Raffaele De Caterina Journal: J Am Coll Cardiol Date: 2017-01-31 Impact factor: 24.094
Authors: Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman Journal: N Engl J Med Date: 2013-11-19 Impact factor: 91.245
Authors: Gerhard Hindricks; Tatjana Potpara; Nikolaos Dagres; Elena Arbelo; Jeroen J Bax; Carina Blomström-Lundqvist; Giuseppe Boriani; Manuel Castella; Gheorghe-Andrei Dan; Polychronis E Dilaveris; Laurent Fauchier; Gerasimos Filippatos; Jonathan M Kalman; Mark La Meir; Deirdre A Lane; Jean-Pierre Lebeau; Maddalena Lettino; Gregory Y H Lip; Fausto J Pinto; G Neil Thomas; Marco Valgimigli; Isabelle C Van Gelder; Bart P Van Putte; Caroline L Watkins Journal: Eur Heart J Date: 2021-02-01 Impact factor: 29.983
Authors: Raffaele De Caterina; Giuseppe Patti; Johan Westerbergh; John Horowitz; Justin A Ezekowitz; Basil S Lewis; Renato D Lopes; John J V McMurray; Dan Atar; M Cecilia Bahit; Matyas Keltai; José L López-Sendón; Witold Ruzyllo; Christopher B Granger; John H Alexander; Lars Wallentin Journal: Eur Heart J Cardiovasc Pharmacother Date: 2022-05-05
Authors: Raffaele De Caterina; Peter Kelly; Pedro Monteiro; Jean Claude Deharo; Carlo de Asmundis; Esteban López-de-Sá; Thomas W Weiss; Johannes Waltenberger; Jan Steffel; Joris R de Groot; Pierre Levy; Ameet Bakhai; Wolfgang Zierhut; Petra Laeis; Michael Kerschnitzki; Paul-Egbert Reimitz; Paulus Kirchhof Journal: BMC Cardiovasc Disord Date: 2019-07-12 Impact factor: 2.298